Lifesci Capital Reaffirms "Market Perform" Rating for Verve Therapeutics (NASDAQ:VERV)

Verve Therapeutics (NASDAQ:VERV - Get Free Report)'s stock had its "market perform" rating reiterated by Lifesci Capital in a report issued on Wednesday,Benzinga reports. They presently have a $12.00 price objective on the stock. Lifesci Capital's price target indicates a potential upside of 5.45% from the stock's current price.

A number of other analysts also recently commented on the company. Guggenheim raised their price objective on Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. HC Wainwright reissued a "neutral" rating and issued a $13.50 target price on shares of Verve Therapeutics in a report on Wednesday. Wall Street Zen raised Verve Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Canaccord Genuity Group cut Verve Therapeutics from a "strong-buy" rating to a "hold" rating and dropped their price target for the company from $39.00 to $13.00 in a report on Tuesday. Finally, Cantor Fitzgerald upgraded Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $14.75.

Verve Therapeutics Trading Up 81.5%

NASDAQ:VERV opened at $11.38 on Wednesday. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -5.39 and a beta of 1.67. Verve Therapeutics has a 1-year low of $2.86 and a 1-year high of $11.41. The business's fifty day moving average price is $5.02 and its 200 day moving average price is $5.84.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.36. The company had revenue of $32.98 million for the quarter, compared to analyst estimates of $7.13 million. Verve Therapeutics had a negative return on equity of 35.81% and a negative net margin of 303.64%. Equities analysts forecast that Verve Therapeutics will post -2.49 earnings per share for the current year.

Institutional Investors Weigh In On Verve Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC boosted its holdings in shares of Verve Therapeutics by 126.2% during the first quarter. Acadian Asset Management LLC now owns 30,803 shares of the company's stock worth $140,000 after acquiring an additional 17,186 shares during the period. Woodline Partners LP bought a new stake in shares of Verve Therapeutics during the first quarter worth approximately $12,648,000. Goldman Sachs Group Inc. boosted its stake in shares of Verve Therapeutics by 90.7% in the first quarter. Goldman Sachs Group Inc. now owns 1,413,118 shares of the company's stock valued at $6,458,000 after buying an additional 671,939 shares during the period. AQR Capital Management LLC boosted its stake in shares of Verve Therapeutics by 1,028.7% in the first quarter. AQR Capital Management LLC now owns 373,207 shares of the company's stock valued at $1,706,000 after buying an additional 340,143 shares during the period. Finally, Alpine Global Management LLC bought a new stake in Verve Therapeutics during the first quarter worth $57,000. Institutional investors own 97.11% of the company's stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.